Financial Contrast: Patient Portal Technologies (OTCMKTS:PPRG) versus Fulgent Genetics (NASDAQ:FLGT)

Fulgent Genetics (NASDAQ:FLGT) and Patient Portal Technologies (OTCMKTS:PPRG) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Risk & Volatility

Fulgent Genetics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Patient Portal Technologies has a beta of 3.77, suggesting that its share price is 277% more volatile than the S&P 500.

Insider and Institutional Ownership

48.1% of Fulgent Genetics shares are held by institutional investors. 31.8% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Fulgent Genetics and Patient Portal Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-16.83%	-2.26%	-2.10%
Patient Portal Technologies	N/A	N/A	N/A

Earnings & Valuation

This table compares Fulgent Genetics and Patient Portal Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$315.55 million	2.89	-$42.71 million	($1.39)	-21.20
Patient Portal Technologies	N/A	N/A	N/A	N/A	N/A

Patient Portal Technologies has lower revenue, but higher earnings than Fulgent Genetics.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Fulgent Genetics and Patient Portal Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1	1	2	0	2.25
Patient Portal Technologies	0	0	0	0	0.00

Fulgent Genetics currently has a consensus price target of $32.00, suggesting a potential upside of 8.59%. Given Fulgent Genetics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Fulgent Genetics is more favorable than Patient Portal Technologies.

Summary

Fulgent Genetics beats Patient Portal Technologies on 6 of the 10 factors compared between the two stocks.

About Fulgent Genetics

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

About Patient Portal Technologies

Patient Portal Technologies, Inc. provides patient relationship management solutions for healthcare facilities, patients and families, and medical personnel. It offers HEALTHCAST, a multi-channel, television network for the delivery of customized information and education to patients, visitors, and staff; MEDEX PRESCRIPTION DELIVERY, a free prescription medication delivery solution; and PHONE & TV RENTAL, an interactive communication center, and billing and collection platform. The company also provides TELCIERGE INSTANT RESPONSE that puts patients in control of non-medical needs through a single phone call; QUICK PULSE SURVEYS that provide feedback for improved operations; and MEDCLIPS, which provide condition specific video clips for internal or remote viewing before or after hospital stay. Patient Portal Technologies, Inc. is based in Baldwinsville, New York.